BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
Business Wire India BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve…